Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Over the last 12 months, insiders at Rhythm Pharmaceuticals, Inc. have bought $0 and sold $15.73M worth of Rhythm Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Rhythm Pharmaceuticals, Inc. have bought $201,713 and sold $16.74M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 10,000 shares for transaction amount of $201,713 was made by Meeker David P (President and CEO) on 2021‑03‑30.
2024-05-09 | Sale | Shulman Joseph | Chief Technical Officer | 3,984 0.0065% | $38.47 | $153,259 | +3.15% | |
2024-04-02 | Sale | German Christopher Paul | Corporate Controller & CAO | 368 0.0006% | $41.76 | $15,368 | -0.54% | |
2024-03-21 | Sale | Shulman Joseph | Chief Technical Officer | 18,235 0.0301% | $40.34 | $735,600 | -1.65% | |
2024-03-20 | Sale | Lee Jennifer Kayden | EVP, Head of North America | 18,235 0.0296% | $38.77 | $707,005 | +0.73% | |
2024-03-19 | Sale | Meeker David P | President and CEO | 45,494 0.0758% | $39.22 | $1.78M | +2.17% | |
2024-03-19 | Sale | Smith Hunter C | Chief Financial Officer | 15,515 0.0259% | $39.22 | $608,498 | +2.17% | |
2024-03-19 | Sale | Cramer Pamela J. | Chief Human Resources Officer | 15,515 0.0259% | $39.22 | $608,498 | +2.17% | |
2024-03-19 | Sale | Lee Jennifer Kayden | EVP, Head of North America | 15,515 0.0259% | $39.22 | $608,498 | +2.17% | |
2024-03-19 | Sale | Mazabraud Yann | EVP, Head of International | 16,000 0.0267% | $39.22 | $627,520 | +2.17% | |
2024-03-19 | Sale | Shulman Joseph | Chief Technical Officer | 15,515 0.0259% | $39.22 | $608,498 | +2.17% | |
2024-02-14 | Sale | Shulman Joseph | Chief Technical Officer | 1,089 0.0018% | $50.01 | $54,461 | -19.40% | |
2024-02-13 | Sale | Smith Hunter C | Chief Financial Officer | 709 0.0011% | $49.82 | $35,322 | -17.48% | |
2024-02-13 | Sale | Lee Jennifer Kayden | EVP, Head of North America | 615 0.001% | $49.83 | $30,645 | -17.48% | |
2024-02-13 | Sale | Mazabraud Yann | EVP, Head of International | 957 0.0015% | $49.84 | $47,697 | -17.48% | |
2024-02-13 | Sale | Shulman Joseph | Chief Technical Officer | 473 0.0008% | $49.84 | $23,574 | -17.48% | |
2024-02-13 | Sale | Shulman Joseph | Chief Technical Officer | 2,338 0.0038% | $49.97 | $116,824 | -17.48% | |
2024-02-13 | Sale | Shulman Joseph | Chief Technical Officer | 1,865 0.003% | $50.00 | $93,250 | -17.48% | |
2024-02-12 | Sale | Smith Hunter C | Chief Financial Officer | 1,209 0.002% | $51.38 | $62,118 | -22.89% | |
2024-02-12 | Sale | Cramer Pamela J. | Chief Human Resources Officer | 696 0.0012% | $51.38 | $35,760 | -22.89% | |
2024-02-12 | Sale | Mazabraud Yann | EVP, Head of International | 1,594 0.0027% | $51.38 | $81,900 | -22.89% |
Meeker David P | President and CEO | 174605 0.2049% | $39.87 | 2 | 2 | <0.0001% |
Smith Hunter C | Chief Financial Officer | 97939 0.1273% | $39.87 | 0 | 12 | |
Cramer Pamela J. | Chief Human Resources Officer | 30005 0.0171% | $39.87 | 0 | 7 | |
Mazabraud Yann | EVP, Head of International | 24495 0.0065% | $39.87 | 0 | 6 | |
Lee Jennifer Kayden | EVP, Head of North America | 6852 0.0051% | $39.87 | 0 | 15 | |
Shulman Joseph | Chief Technical Officer | 30 0.0044% | $39.87 | 0 | 16 | |
German Christopher Paul | Corporate Controller & CAO | 795 0.0013% | $39.87 | 0 | 1 | |
MOTT DAVID M | 10 percent owner | 4909956 8.3084% | $39.87 | 1 | 0 | +9.57% |
BARRIS PETER J | 10 percent owner | 4909956 8.3084% | $39.87 | 1 | 0 | +9.57% |
BASKETT FOREST | 10 percent owner | 4909956 8.3084% | $39.87 | 1 | 0 | +9.57% |
BARRETT M JAMES | 10 percent owner | 4909956 8.3084% | $39.87 | 1 | 0 | +9.57% |
SANDELL SCOTT D | 10 percent owner | 4909956 8.3084% | $39.87 | 1 | 0 | +9.57% |
KERINS PATRICK J | 10 percent owner | 4909956 8.3084% | $39.87 | 1 | 0 | +9.57% |
Viswanathan Ravi | 10 percent owner | 4909956 8.3084% | $39.87 | 1 | 0 | +9.57% |
NEW ENTERPRISE ASSOCIATES 13 LP | 10 percent owner | 4909956 8.3084% | $39.87 | 1 | 0 | +9.57% |
RA CAPITAL MANAGEMENT, L.P. | 4360860 7.3792% | $39.87 | 0 | 8 | ||
ORBIMED ADVISORS LLC | 10 percent owner | 2750079 4.6535% | $39.87 | 1 | 3 | +9.57% |
MPM BIOVENTURES V, L.P. | 10 percent owner | 2696392 4.5627% | $39.87 | 1 | 0 | +9.57% |
BAKER BROS. ADVISORS LP | 1878242 3.1783% | $39.87 | 1 | 0 | <0.0001% | |
PFIZER INC | 10 percent owner | 1427639 2.4158% | $39.87 | 1 | 0 | +9.57% |
Foley Todd | director | 909258 1.5386% | $39.87 | 1 | 44 | +9.57% |
Ipsen, S.A. | 10 percent owner | 833099 1.4097% | $39.87 | 1 | 0 | +9.57% |
Gottesdiener Keith Michael | CEO & President | 506342 0.8568% | $39.87 | 0 | 15 | |
Flynn James E | 10 percent owner | 468505 0.7928% | $39.87 | 1 | 0 | +9.57% |
Desikan Nithya | Chief Commercial Officer | 43602 0.0738% | $39.87 | 0 | 2 | |
Van der Ploeg Leonardus H.T. | Chief Scientific Officer | 42339 0.0716% | $39.87 | 0 | 7 | |
Roberts William T. | Chief Accounting Officer | 7872 0.0133% | $39.87 | 0 | 3 |
PRIMECAP Management Co | $335.7M | 12.71 | 7.75M | -3.79% | -$13.22M | 0.25 | |
BlackRock | $282.93M | 10.71 | 6.53M | +2.8% | +$7.71M | 0.01 | |
Baker Bros Advisors LP | $277.24M | 10.49 | 6.4M | 0% | +$0 | 3.48 | |
RA Capital Management, L.P. | $230.97M | 8.74 | 5.33M | 0% | +$0 | 0.23 | |
Goldman Sachs | $221.49M | 8.38 | 5.11M | +1.26% | +$2.76M | 0.04 | |
The Vanguard Group | $143.17M | 5.42 | 3.3M | +2.39% | +$3.35M | <0.01 | |
Perceptive Advisors | $141.63M | 5.36 | 3.27M | +51.74% | +$48.29M | 0.09 | |
State Street | $130.59M | 4.94 | 3.01M | +36.62% | +$35M | 0.01 | |
Nea Management Company Llc | $126.09M | 4.77 | 2.91M | 0% | +$0 | 1.45 | |
Frazier Life Sciences Management L P | $94.9M | 3.59 | 2.19M | -7.64% | -$7.85M | 4.87 | |
Federated Hermes | $71.98M | 2.72 | 1.66M | -28.12% | -$28.16M | 0.17 | |
ROCK SPRINGS CAPITAL MANAGEMENT, LP | $65.99M | 2.5 | 1.52M | 0% | +$0 | 1.68 | |
Polar Capital | $65M | 2.46 | 1.5M | -14.29% | -$10.83M | 0.36 | |
Geode Capital Management | $51.17M | 1.94 | 1.18M | +5.5% | +$2.67M | 0.01 | |
Commodore Capital, LP | $45.5M | 1.72 | 1.05M | -32.26% | -$21.66M | 3.21 | |
Driehaus Capital Management LLC | $37.07M | 1.4 | 855,505 | +42.84% | +$11.12M | 0.37 | |
Healthcare Of Ontario Pension Plan Trust Fund | $31.66M | 1.2 | 730,643 | +381.18% | +$25.08M | 0.11 | |
OrbiMed | $30.54M | 1.16 | 704,842 | +31.34% | +$7.29M | 0.62 | |
Janus Henderson | $26.93M | 1.02 | 621,427 | -0.07% | -$20,147.99 | 0.02 | |
Canada Pension Plan Investment Board | $25M | 0.95 | 577,000 | +116.11% | +$13.43M | 0.03 | |
Cormorant Asset Management Lp | $23.83M | 0.9 | 550,000 | 0% | +$0 | 1.13 | |
Opaleye Management Inc | $22.31M | 0.85 | 515,000 | -15.57% | -$4.12M | 3.52 | |
Northern Trust | $21.79M | 0.83 | 502,855 | +0.35% | +$76,304.13 | <0.01 | |
T. Rowe Price | $20.86M | 0.79 | 481,533 | -15.86% | -$3.93M | <0.01 | |
Voloridge Investment Management, LLC | $20.51M | 0.78 | 473,455 | +30.53% | +$4.8M | 0.05 | |
Charles Schwab | $17.62M | 0.67 | 406,745 | +2.28% | +$392,569.80 | <0.01 | |
National Bank Of Canada Fi | $14.38M | 0.6 | 367,517 | +53.77% | +$5.03M | 0.02 | |
Assenagon Asset Management S.A. | $12.38M | 0.47 | 285,651 | -5.3% | -$692,630.06 | 0.03 | |
Lord Abbett | $12.18M | 0.46 | 281,157 | -0.83% | -$102,297.66 | 0.04 | |
Artisan Partners | $11.76M | 0.45 | 271,421 | 0% | +$0 | 0.02 | |
Franklin Templeton Investments | $9.57M | 0.36 | 220,905 | +3,659.45% | +$9.32M | <0.01 | |
Rafferty Asset Management Llc | $9.47M | 0.36 | 218,657 | +79.74% | +$4.2M | 0.03 | |
Ubs Asset Management Americas Inc | $8.97M | 0.34 | 206,980 | -1.41% | -$128,170.15 | <0.01 | |
Wellington Management Company | $8.39M | 0.32 | 193,523 | +38.43% | +$2.33M | <0.01 | |
Citigroup | $8.26M | 0.31 | 190,520 | +250.87% | +$5.9M | 0.01 | |
Silverarc Capital Management Llc | $7.96M | 0.3 | 183,776 | +5.47% | +$412,848.24 | 2.35 | |
Morgan Stanley | $7.92M | 0.3 | 182,870 | -21.06% | -$2.11M | <0.01 | |
Samsara Biocapital Llc | $7.48M | 0.28 | 172,647 | 0% | +$0 | 1.17 | |
Woodline Partners LP | $7.46M | 0.28 | 172,207 | +130.07% | +$4.22M | 0.07 | |
UBS | $7.43M | 0.28 | 171,565 | +99.6% | +$3.71M | <0.01 | |
Voya Investment Management LLC | $7.35M | 0.28 | 169,711 | +161.13% | +$4.54M | 0.01 | |
BNY Mellon | $7.27M | 0.28 | 167,838 | -6.87% | -$536,598.83 | <0.01 | |
NISA Investment Advisors, LLC | $6.3M | 0.24 | 145,291 | +11,467.75% | +$6.24M | 0.04 | |
Nuveen | $6.18M | 0.23 | 142,735 | -0.65% | -$40,470.22 | <0.01 | |
Barclays | $5.53M | 0.21 | 127,536 | -49.27% | -$5.37M | <0.01 | |
GHOST TREE CAPITAL LLC | $5.42M | 0.21 | 125,000 | New | +$5.42M | 1.76 | |
Bank of America | $4.81M | 0.18 | 111,114 | +59.03% | +$1.79M | <0.0001 | |
Squarepoint Ops LLC | $4.71M | 0.18 | 108,755 | +608.5% | +$4.05M | 0.02 | |
JGP Global Gestao de Recursos Ltda. | $4.58M | 0.17 | 105,814 | +1,760.3% | +$4.34M | 3.17 | |
Susquehanna International Group | $4.47M | 0.17 | 103,253 | +220.34% | +$3.08M | 0.01 |